I-Mab Crecimiento futuro

Future controles de criterios 0/6

Se prevé un crecimiento anual de los beneficios y los ingresos de I-Mab de 0.1% y 29.3% respectivamente, mientras que el BPA crecerá en un 12% al año.

Información clave

1.9%

Tasa de crecimiento de los beneficios

19.7%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	34.8%
Tasa de crecimiento de los ingresos	47.1%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	13 Sep 2024

Actualizaciones recientes sobre el crecimiento futuro

No hay actualizaciones

Recent updates

Previsiones de crecimiento de beneficios e ingresos

DB:0VY - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	N/A	-106	-59	N/A	3
12/31/2025	N/A	-75	-53	N/A	3
12/31/2024	N/A	-35	-40	N/A	3
6/30/2024	3	-206	N/A	N/A	N/A
3/31/2024	4	-205	N/A	N/A	N/A
12/31/2023	4	-206	-185	-184	N/A
9/30/2023	-15	-253	N/A	N/A	N/A
6/30/2023	-35	-295	N/A	N/A	N/A
3/31/2023	-35	-331	N/A	N/A	N/A
12/31/2022	-32	-364	-167	-160	N/A
9/30/2022	-7	-338	N/A	N/A	N/A
6/30/2022	18	-344	-171	-164	N/A
3/31/2022	17	-365	-169	-164	N/A
12/31/2021	14	-367	-158	-153	N/A
9/30/2021	247	-103	45	48	N/A
6/30/2021	242	-4	51	53	N/A
3/31/2021	237	34	58	59	N/A
12/31/2020	236	72	65	66	N/A
9/30/2020	N/A	-140	-119	-118	N/A
6/30/2020	2	-171	-119	-117	N/A
3/31/2020	3	-190	-121	-120	N/A
12/31/2019	4	-213	-126	-125	N/A
9/30/2019	6	-172	-111	-109	N/A
6/30/2019	7	-159	-90	-88	N/A
3/31/2019	8	-111	-68	-66	N/A
12/31/2018	8	-59	-43	-41	N/A
12/31/2017	2	-46	N/A	-39	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que 0VY siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que 0VY siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que 0VY siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que 0VY no tenga ingresos el año que viene.

Ingresos de alto crecimiento: Se prevé que 0VY no tenga ingresos el año que viene.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de 0VY se prevé que sea elevada dentro de 3 años.

I-Mab Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

I-Mab Presents Updated Phase 1 Givastomig Data at ESMO 2024

First half 2024 earnings released: US$0.19 loss per share (vs US$1.32 loss in 1H 2023)

I-Mab to Report First Half, 2024 Results on Aug 28, 2024

New minor risk - Market cap size

Insufficient new directors

I-Mab Announces Board and Committee Changes

I-Mab Appoints Phillip Dennis as Chief Medical Officer

I-mab Biopharma (Hangzhou) Co., Ltd. completed the acquisition of I-Mab Biopharma (Shanghai) Co., Ltd. from I-Mab (NasdaqGM:IMAB).

Full year 2023 earnings released: CN¥16.53 loss per share (vs CN¥29.23 loss in FY 2022)

New minor risk - Financial data availability

I-mab Biopharma (Hangzhou) Co., Ltd. agreed to acquire I-Mab Biopharma (Shanghai) Co., Ltd. from I-Mab (NasdaqGM:IMAB) for $80 million.

I-Mab Announces Board Changes , Effective February 10, 2024

I-Mab and Hi-Bio Announces That the U.S. Food and Drug Administration Has Granted Breakthrough Therapy Designation for Felzartamab, an Investigational Cd38 Antibody, for the Treatment of Primary Memorbranous Nephropathy (PMN)

I-Mab Announces Phase 1 Data of Givastomig at Esmo 2023

I-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1Bb Bispecific Antibody Tj-L14b Abl503

New major risk - Share price stability

I-Mab (NasdaqGM:IMAB) announces an Equity Buyback for $40 million worth of its shares.

I-Mab to Report First Half, 2023 Results on Aug 17, 2023

I-Mab Announces the Appointment of Raj Kannan as Member of the Board of Directors

TRACON Pharmaceuticals, Inc. Announces Enforcement Action to Collect Binding Arbitration Award from I-Mab Biopharma

First half 2022 earnings released: CN¥12.75 loss per share (vs CN¥14.67 loss in 1H 2021)

Less than half of directors are independent

I-Mab Announces Management Changes

I-Mab Announces Executive Changes

I-Mab(NasdaqGM:IMAB) dropped from FTSE All-World Index (USD)

I-Mab Announces Approval from China CDE to Initiate Phase 3 Registrational Study of Lemzoparlimab in Combination with Azacitidine in Higher-Risk Myelodysplastic Syndrome

I-Mab Announces Positive Phase 2 Data of Lemzoparlimab in Combination with Azacitidine (AZA) in Patients with Higher Risk Myelodysplastic Syndrome at ESMO 2022

I-Mab (NasdaqGM:IMAB) announces an Equity Buyback for $40 million worth of its shares.

I-Mab to Report First Half, 2022 Results on Aug 30, 2022

I-Mab Announces First Patient Dosed in Phase 1 Clinical Trial of Claudin 18.2 and 4-1Bb Bispecific Antibody TJ-CD4B in Solid Tumors in China

Genexine Announces Completion of Enrollment in Phase 3 Clinical Trial with Its Proprietary Long-acting Growth Hormone, GX-H9/TJ101 (Eftansomatropin alfa)

I-Mab Announces Completion of Patient Enrollment in Phase III Clinical Trial of Eftansomatropin Alfa for Treatment of Pediatric Growth Hormone Deficiency

I-Mab Reports Latest Phase 2 Clinical Data of its Differentiated CD73 Antibody Uliledlimab

I-Mab to Hold Investor Call to Report Latest Phase 2 Clinical Data of its Differentiated CD73 Antibody Uliledlimab

I-Mab Reportedly Exploring Possible Sale Amid Takeover Interest

I-Mab Announces First Patient Dosed in China Phase 2 Combination Trial of Lemzoparlimab with Toripalimab in Patients with Advanced Solid Tumors

I-Mab Announces First Patient Dosed in China Phase 2 Clinical Trial of Efineptakin Alfa in Combination with Pembrolizumab in Advanced Solid Tumors

I-Mab Announces IND Approval from China NMPA for Phase 2 Clinical Trial of Enoblituzumab in Combination with Pembrolizumab in Solid Tumors

I-Mab Receives IND Approval for Phase 1 Clinical Trial of Bispecific Antibody TJ-CD4B in Solid Tumors in China

I-Mab Presents Interim Clinical Data of Lemzoparlimab in Combination with Rituximab in Relapsed and Refractory Non-Hodgkin Lymphoma At ASH 2021

I-Mab Announces First Patient Dosed in U.S. Phase 1 Study of Protollin for the Treatment of Alzheimer's Disease

I-Mab Announces First Two Patients Dosed in U.S. Phase 2 Combination Trial of Uliledlimab with Atezolizumab in Patients with Selected Advanced Solid Tumors

I-Mab Announces Acceptance of IND Application from China NMPA for Phase 2 Clinical Trial of Enoblituzumab in Combination with Pembrolizumab in Solid Tumors

Investor sentiment deteriorated over the past week

I-Mab Reports Positive Interim Analysis from Phase 2/3 Study of Its GM-CSF Antibody Plonmarlimab (TJM2) to Treat Patients with Severe Covid-19

Investor sentiment deteriorated over the past week

I-Mab Announces Multiple Advancements of 4-1BB Bispecific Antibody Portfolio

I-Mab Announces China NMPA Approval for Phase 1b Trial of Felzartamab in Systemic Lupus Erythematosus

I-Mab Presents Phase 1 Data on Highly Differentiated CD73 Antibody Uliledlimab at ASCO 2021

I-Mab Announces First Patient Dosed in China Phase 2 Combination Trial of Lemzoparlimab with Azacitidine in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS CN¥8.07 (vs CN¥463 loss in FY 2019)

I-Mab Announces Positive Topline Phase 2 Results for Olamkicept in Ulcerative Colitis

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS CN¥8.07 (vs CN¥463 loss in FY 2019)

I-Mab to Present Differentiated Mechanism of Action and Preclinical Data for Anti-CD73 Antibody Uliledlimab At 2021 American Association for Cancer Research Annual Meeting

I-Mab to Report Fiscal Year 2020 Results on Mar 29, 2021

I-Mab Announces First Patient Dosed in China Phase 3 Study of Eftansomatropin Alfa in Pediatric Patients with Growth Hormone Deficiency

I-Mab Announces China NMPA Clearance for Phase 1 Study of TJ210/MOR210 in Patients with Advanced Solid Tumors

I-Mab has completed a Follow-on Equity Offering in the amount of $177.3333 million.

I-Mab Announces Multiple Clinical Advancements of its Differentiated CD73 Antibody Uliledlimab in China and the U.S

I-Mab Announces First Patient Dosed in Phase 2 Clinical Trial of TJ107 in Glioblastoma Multiforme in China

New 90-day high: €51.00

I-Mab and MorphoSys Announce First Patient Dosed in U.S. Phase 1 Study of TJ210/MOR210 in Patients with Advanced Cancer

New 90-day high: €37.60

Revenue in line with expectations

I-Mab Accelerates Clinical Development of Anti-CD47 Monoclonal Antibody Lemzoparlimab in the US and China

Revenue in line with expectations

I-Mab Announces Appointments to its Scientific Advisory Board

I-Mab Announces Preclinical Data on Differentiated Anti-C5aR Antibody TJ210/MOR210 at SITC 2020

I-Mab Reports Phase 1 Clinical Trial Data of Highly Differentiated Anti-CD47 Monoclonal Antibody Lemzoparlimab at the 2020 SITC Annual Meeting

I-Mab to Present Preclinical Data of TJ210 at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting

I-Mab to Present Phase 1 Data of Lemzoparlimab at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting

I-Mab Receives China CDE Approval to Initiate Phase 3 Clinical Trial of Eftansomatropin in Pediatric Patients with Growth Hormone Deficiency

New 90-day high: €39.80